Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma

Por Sabado, Rachel L, Pavlick, Anna, Gnjatic, Sacha, Cruz, Crystal, Vengco, Isabelita, Hasan, Farah, Darvishian, Farbod, Chiriboga, Luis, Holman, Rose Marie, Escalon, Juliet, Muren, Caroline, Escano, Crystal, Yepes, Ethel, Sharpe, Dunbar, Adams, Sylvia, Ott, Patrick, Jungbluth, Achim, Pan, Linda, Venhaus, Ralph, Bhardwaj, Nina
Publicado em 2013

Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High Risk Melanoma

Por Sabado, Rachel Lubong, Pavlick, Anna, Gnjatic, Sacha, Cruz, Crystal M., Vengco, Isabelita, Hasan, Farah, Spadaccia, Meredith, Darvishian, Farbod, Chiriboga, Luis, Holman, Rose Marie, Escalon, Juliet, Muren, Caroline, Escano, Crystal, Yepes, Ethel, Sharpe, Dunbar, Vasilakos, John P., Rolnitzsky, Linda, Goldberg, Judith, Mandeli, John, Adams, Sylvia, Jungbluth, Achim, Pan, Linda, Venhaus, Ralph, Ott, Patrick A., Bhardwaj, Nina
Publicado no Cancer Immunol Res (2015)